Key Stats for CVS Health Stock
- Past-Week Performance: 0.2%
- 52-Week Range: $58 to $85
- Current Price: $78
- Valuation Model Target: $124
What Happened to CVS Health Stock?
CVS Health stock (CVS) peaked near $84 in late January 2026 before falling sharply around January 25–28, recovering to $78.20 by February 17, and returning -2.4% year-to-date on a past-week gain of 0.17%.
The company reported Q4 2025 adjusted EPS of $1.09 on February 10, 2026, beating the IBES estimate of $0.99, alongside Q4 revenue of $105.7B, which exceeded the $103.6B analyst estimate.
Full-year 2025 revenue reached a record $402.1B, up 7.8% year-over-year, with pharmacy business profit growing 5% in FY2025 after declining approximately 5% annually for the prior five years.
CVS reaffirmed its 2026 adjusted EPS guidance of $7.00–$7.20 and revenue of at least $400B on February 10, unchanged from December guidance, while management signaled it could surpass those targets.
The House Judiciary Committee subpoenaed CVS Health on February 10, 2026, alongside seven other health insurers, for documents related to a potential Obamacare subsidy fraud investigation, with submissions due by February 23, 2026.
Bloomberg News also reported on January 21 that US Republican lawmakers stated CVS Health may have violated antitrust laws; no additional details beyond the headline were provided in the supplied materials.
Furthermore, Mubadala Investment Co raised its CVS Health stake by 17.3% to 149,769 shares as of December 31, 2025, per SEC filing disclosed February 17, 2026; guidance and strategy remained unchanged following this disclosure.
Buy and Outperform ratings combined total 22 out of 27 analysts as of February 17. The consensus mean target of $95 sits 21.3% above the current $78.20 close. Hold ratings ticked up from 4 to 5 since December 2025, with zero active Sell ratings on record.
Truist (TFC), Morgan Stanley (MS), RBC Capital Markets (RY), and BofA (BAC) all maintained positive ratings on CVS following the February 10 earnings release, with analyst commentary highlighting turnaround progress, Medicare Advantage margin momentum, and maintained 2026 guidance.
What the Market is Telling Us About CVS Stock
CVS peaked near $84 in late January 2026 before pulling back to $78 by February 17, returning (2.4%) year-to-date.
- Earnings beat on both lines: Q4 adjusted EPS of $1.09 beat the $0.99 estimate and Q4 revenue of $105.7B beat the $103.6B estimate, signaling operational progress.
- Turnaround gaining ground: Pharmacy profit grew 5% in FY2025 after five consecutive years of annual declines, and operating income recovered 24.9% after collapsing 43% in FY2024.
- Zero Sell ratings: 22 of 27 covering analysts hold Buy or Outperform ratings as of February 17, 2026, with no active Sell ratings on record.
Management reaffirmed 2026 guidance and signaled it could surpass targets, while CFO Brian Newman highlighted a deliberate focus on setting realistic targets and delivering against them.
Two active legal overhangs remained during the period: a House Judiciary subpoena tied to Obamacare fraud allegations due February 23, and a Bloomberg-reported antitrust allegation from Republican lawmakers filed January 21.
Mubadala Investment raised its CVS stake by 17.3% to 149,769 shares as of December 31, 2025, per SEC filing, while four major brokerages maintained positive ratings following the February 10 earnings release.
CVS is down (2.4%) YTD despite a record FY2025 revenue of $402.1B. Operating income recovered to $10.02B in FY2025 but margins remain at 2.5%, well below the 4.9% seen in FY2021-2022.
The February 23 subpoena deadline and any developments on the antitrust allegation are the next disclosed events to watch, alongside execution against the 2026 guidance range of $7.00 to $7.20 adjusted EPS.
How Much Upside Does CVS Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
